

Prevnar 13™ Pneumococcal Vaccine (PCV13)




<p>Indications for Use and Schedule</p> <ul style="list-style-type: none"> Routinely administer to children 2 through 56 months of age <p>Recommended Schedule:</p> <ul style="list-style-type: none"> Doses at 2, 4, 6 months, booster dose at 12-15 months of age and at least 2 months after the third dose First dose as early as 6 weeks Unvaccinated children 7 months of age or older require fewer doses (see chart 1 below) <p>PCV13 can be administered at the same time as other routine childhood vaccinations if administered in a separate syringe at a separate injection site. The safety and efficacy of concurrent administration of PCV13 and PPSV23 has not been studied, and concurrent administration is not recommended. Separate PCV and PPSV23 vaccines by 8 weeks.</p>	<p>Vaccine Administration</p> <ul style="list-style-type: none"> Intramuscular (IM) 0.5-ml dose injection in the deltoid of the arm 1-1^{1/2} inch, 22-25 gauge needle Professional judgment is appropriate when selecting needle length Can be given simultaneously with other vaccines <p>Storage and Handling</p> <ul style="list-style-type: none"> Store in the refrigerator between 35°-46° F (2°-8°C) Do NOT freeze Keep in the original box Shake well before use Open multi-dose vials may be used until the expiration printed on package unless visibly contaminated. <div style="text-align: right;">  </div>
---	---

CHART 1- SCHEDULE FOR UNVACCINATED OLDER CHILDREN

Age	Number of Doses	Recommended Interval between doses
7 through 11 months	3	4 weeks between dose 1 and 2 Dose 3 at 12 through 15 months, at least 8 weeks after second dose
12 through 23 months	2	At least 8 weeks between doses
24 months and older	1	
24 through 71 months with underlying medical conditions*	2	At least 8 weeks between doses

*These conditions include chronic heart and lung disease, diabetes, cerebrospinal fluid leak, cochlear implant, sickle cell disease and other hemoglobinopathies, functional or anatomic asplenia, HIV infection or immunocompromising conditions resulting from disease or treatment of a disease.

CONTRAINDICATIONS

- Severe allergic reaction to any component of Prevnar 13, Prevnar, or any diphtheria toxoid-containing vaccine.
- Moderate or severe illness

PRECAUTIONS

Apnea following intramuscular vaccination has been observed in some infants born prematurely. Decisions about when to administer an intramuscular vaccine, including PCV13, to infants born prematurely should be based on consideration of the individual infant's medical status and potential benefits and possible risks of vaccination

FURTHER POINTS

- May be administered simultaneously with influenza vaccine
- Local reactions (such as pain, swelling or redness) following PCV13 occur in up to half of recipients. Local reactions are generally more common with the fourth dose than with the first three doses.
- When elective splenectomy, immunocompromising therapy, or cochlear implant placement is being planned, PCV13 vaccination should be completed at least 2 weeks before surgery or initiation of therapy.
- CPT code:** 90670. **ICD-9-CM code:** V03.82
- PCV Vaccine Information Statement (VIS), can be found at <http://www.immunize.org/vis/>

For more information on Prevnar 13 please view The ACIP recommendation at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5911a1.htm?s_cid=rr5911a1_e for additional information at www.cdc.gov/vaccines